Director sold ~$520K of ResMed|
Scheduled in advanceLoading…
Traded Feb 4, 2026 · Filed Feb 6, 2026
ResMed|'s Global General Counsel sold $13K of ResMed| shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$13,000
Shares × reported transaction price
6 days after results of Jan 29, 2026, 85 days before results of Apr 30, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $263.03 on Feb 4, 2026, 29% above its 52-week low and 10% below its high, after a 7% rise over the previous 30 trading days
52-week range $204.54 (Apr 8, 2025) to $293.73 (Aug 22, 2025), 66% of the way up, from 251 adjusted closes. 30 trading days earlier: $244.94 on Dec 19, 2025. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -7.3% | -1.6% | -5.7% |
| 30 days | -13.0% | -2.5% | -10.4% |
| 90 days | -28.0% | +6.5% | -34.5% |
| 180 days | -20.3% | +11.4% | -31.7% |
Past results only. Not a forecast.
Director sold ~$520K of ResMed|
Scheduled in advanceDerivative exercise or conversion — not an open-market buy.